How big is Fortress Biotech, Inc.?

As of Jun 18, Fortress Biotech, Inc. has a market capitalization of 54.11 million and reported net sales of 57.79 million, with a net loss of 106.52 million over the latest four quarters. Shareholder's funds are 22.74 million, and total assets amount to 144.22 million.

As of Jun 18, Fortress Biotech, Inc. has a market capitalization of 54.11 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 57.79 million for the latest four quarters, while the consolidated net profit for the same period was a loss of 106.52 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 22.74 million and total assets amounting to 144.22 million.

What does Fortress Biotech, Inc. do?

Fortress Biotech, Inc. is a micro-cap biopharmaceutical company focused on acquiring, developing, and commercializing novel pharmaceutical and biotechnology products. As of March 2025, it reported net sales of $13 million and a net loss of $25 million, with a market cap of $54.11 million.

Overview: <BR>Fortress Biotech, Inc. is a biopharmaceutical company that acquires, develops, and commercializes novel pharmaceutical and biotechnology products, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 13 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -25 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 54.11 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.39 <BR>Return on Equity: -482.55% <BR>Price to Book: 2.43<BR><BR>Contact Details: <BR>Address: 2 Gansevoort St Fl 9, NEW YORK NY: 10014-1667 <BR>Tel: 1 781 6524500 <BR>Fax: 1 781 6524545 <BR>Website: http://www.fortressbiotech.com

Should I buy, sell or hold Fortress Biotech, Inc.?

Who are in the management team of Fortress Biotech, Inc.?

As of March 2022, Fortress Biotech, Inc.'s management team includes Dr. Lindsay Rosenwald (Executive Chairman, CEO), Dr. Eric Rowinsky (Co-Vice Chairman), Mr. Michael Weiss (Executive Vice Chairman), and several independent directors. They are responsible for the company's strategic direction and operations.

As of March 2022, the management team of Fortress Biotech, Inc. includes the following individuals:<BR><BR>- Dr. Lindsay Rosenwald: Executive Chairman of the Board, President, Chief Executive Officer<BR>- Dr. Eric Rowinsky: Co-Vice Chairman and Director<BR>- Mr. Michael Weiss: Executive Vice Chairman - Strategic Development, Director<BR>- Dr. Jimmie Harvey: Independent Director<BR>- Mr. Malcolm Hoenlein: Independent Director<BR>- Mr. Dov Klein: Independent Director<BR>- Mr. J. Jay Lobell: Independent Director<BR>- Mr. Kevin Lorenz: Independent Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Is Fortress Biotech, Inc. overvalued or undervalued?

Fortress Biotech, Inc. is considered overvalued and risky due to negative financial metrics, including a Price to Book Value of 2.66, an alarming -482.55% Return on Equity, and a troubling 5-year return of -95.03%, despite a strong 85.42% return over the past year.

As of 10 May 2016, the valuation grade for Fortress Biotech, Inc. moved from does not qualify to risky. The company is considered overvalued given its negative financial metrics and poor performance compared to peers. The Price to Book Value stands at 2.66, while the EV to EBITDA is -0.31, indicating significant valuation challenges. Additionally, the company's Return on Equity (ROE) is an alarming -482.55%, further underscoring its financial instability.<BR><BR>In comparison to peers, Fortress Biotech's EV to EBITDA ratio is better than Assembly Biosciences, Inc. at -6.6467 and Sol-Gel Technologies Ltd. at -11.1084, but still reflects a concerning trend. The stock has shown a strong return of 85.42% over the past year, significantly outperforming the S&P 500's 17.14% return, although its longer-term performance remains troubling with a 5-year return of -95.03%.

Is Fortress Biotech, Inc. technically bullish or bearish?

As of August 11, 2025, Fortress Biotech, Inc. shows a bullish technical trend driven by moving averages and MACD indicators, despite a bearish monthly RSI, having significantly outperformed the S&P 500 recently while underperforming over the longer term.

As of 11 August 2025, the technical trend for Fortress Biotech, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages also indicate a bullish stance. However, the monthly RSI is bearish, which presents a mixed signal. The Bollinger Bands show a bullish trend on a monthly basis and mildly bullish on a weekly basis. The KST is bullish weekly and mildly bullish monthly, while the Dow Theory indicates a mildly bullish trend monthly with no trend weekly. <BR><BR>In terms of performance, the stock has significantly outperformed the S&P 500 over the past month (58.22% vs. 2.33%) and year (85.42% vs. 17.14%), but has underperformed over the longer three and five-year periods. Overall, the current technical stance is bullish, with strength primarily driven by the moving averages and MACD indicators.